An interventional study of Laparoscopic splenectomy and azygoportal disconnection in Cirrhosis, Liver and Splenectomy; Status, sponsored by Northern Jiangsu People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by Northern Jiangsu People's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital — 8 open to participants now, 8 under way, none of them phase 3. Liver Cirrhosis · Northern Jiangsu People's Hospital.
Among the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital, this one is one of 6 that started in 2022, is one of 5 with no phase, and was the 4th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →8 of the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Northern Jiangsu People's Hospital · Sites in China
Ages 18–80
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 6 started in 2022.
This study's planned enrollment of 20 is below the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 20 across the 5 interventional studies, 85 across the 6 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northern Jiangsu People's Hospital is the lead sponsor of 61 studies on the registry; 31 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Liver Cirrhosis by Northern Jiangsu People's Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study, the investigators compared the improvement of immune function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative immune function and improve patient prognosis.
The patients were enrolled according to the research criteria, and collected the general basic information of the patients. After the preoperative preparation was perfected, the same surgical team performed laparoscopic splenectomy and azygoportal disconnection, and the same nursing team performed the nursing after the operation. Then, patients received a unified treatment plan after surgery, including medication, other treatments and follow-up. During the treatment, the immune function related indicators of the patients were monitored before surgery, 3, 6, 12 and 24 months after surgery, including the counts of leukocytes, neutrophils, lymphocytes, and monocytes, and the levels of CD4+,CD8+,CD4+/CD8+, and CD19,CD20.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
Procedure: Laparoscopic splenectomy and azygoportal disconnection
Laparoscopic splenectomy and azygoportal disconnection is performed by the same surgical team.
The immune function CD4+ at 3 months after surgery
The level of the immune function CD4+ at 3 months after surgery
Time frame: 3 months
The immune function CD4+ at 6 months after surgery
The level of the immune function CD4+ at 6 months after surgery
Time frame: 6 months
The immune function CD4+ at 12 months after surgery
The level of the immune function CD4+ at 12 months after surgery
Time frame: 12 months
The immune function CD4+ at 24 months after surgery
The level of the immune function CD4+ at 24 months after surgery
Time frame: 24 months
The immune function CD8+ at 3 months after surgery
The level of the immune function CD8+ at 3 months after surgery
Time frame: 3 months
The immune function CD8+ at 6 months after surgery
The level of the immune function CD8+ at 6 months after surgery
Time frame: 6 months
The immune function CD8+ at 12 months after surgery
The level of the immune function CD8+ at 12 months after surgery
Time frame: 12 months
The immune function CD8+ at 24 months after surgery
The level of the immune function CD8+ at 24 months after surgery
Time frame: 24 months
The immune function CD4+/CD8+ at 3 months after surgery
The level of the immune function CD4+/CD8+ at 3 months after surgery
Time frame: 3 months
The immune function CD4+/CD8+ at 6 months after surgery
The level of the immune function CD4+/CD8+ at 6 months after surgery
Time frame: 6 months
The immune function CD4+/CD8+ at 12 months after surgery
The level of the immune function CD4+/CD8+ at 12 months after surgery
Time frame: 12 months
The immune function CD4+/CD8+ at 24 months after surgery
The level of the immune function CD4+/CD8+ at 24 months after surgery
Time frame: 24 months
The immune function CD19 at 3 months after surgery
The level of the immune function CD19 at 3 months after surgery
Time frame: 3 months
The immune function CD19 at 6 months after surgery
The level of the immune function CD19 at 6 months after surgery
Time frame: 6 months
The immune function CD19 at 12 months after surgery
The level of the immune function CD19 at 12 months after surgery
Time frame: 12 months
The immune function CD19 at 24 months after surgery
The level of the immune function CD19 at 24 months after surgery
Time frame: 24 months
The immune function CD20 at 3 months after surgery
The level of the immune function CD20 at 3 months after surgery
Time frame: 3 months
The immune function CD20 at 6 months after surgery
The level of the immune function CD20 at 6 months after surgery
Time frame: 6 months
The immune function CD20 at 12 months after surgery
The level of the immune function CD20 at 12 months after surgery
Time frame: 12 months
The immune function CD20 at 24 months after surgery
The level of the immune function CD20 at 24 months after surgery
Time frame: 24 months
Started Mar 2022 (actual). Primary completion is estimated for Jul 2025, 40 months after the start.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 40 months is above that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Northern Jiangsu People's Hospital